Aqueous formulations of a cardiac p2x receptor agonist and their use in treating medical disorders
AssigneeComovus Pharmaceuticals, Inc.
InventorsBruce T. Liang, Mingliu Lei, Hongjuan Xue, Yinan Han, Wenjie Song, Menghua Li
Life of this patent
Estimating the term…
Abstract
The invention provides aqueous formulations containing a compound that stimulates cardiac P2X receptor activity, and methods for their use in stimulating cardiac P2X receptor activity and treating medical disorders, such as heart failure.
Claims49
An aqueous formulation, comprising:
- (a) from 0.25% (w/v) to 0.75% (w/v) of a compound of Formula I, wherein Formula I is represented by:
- or a pharmaceutically acceptable salt thereof;
- (b) from 0.01% (w/v) to 0.03% (w/v) of a chelating agent selected from ethylenediamine tetraacetic acid, a pharmaceutically acceptable salt of ethylenediamine tetraacetic acid, or a mixture thereof;
- (c) from 10 mM to 30 mM of a buffer comprising citric acid and a pharmaceutically acceptable salt of citric acid;
- (d) from 3.5% (w/v) to 11% (w/v) of a tonicity modifier;
- and
- (e) at least 90% (w/v) water;
- and
- having a pH in the range of 7.5 to 8.5.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An aqueous formulation, comprising:
- (a) about 0.5% (w/v) of a compound of Formula I, wherein Formula I is represented by:
- or a pharmaceutically acceptable salt thereof;
- (b) about 0.02% (w/v) of a chelating agent selected from ethylenediamine tetraacetic acid, a pharmaceutically acceptable salt of ethylenediamine tetraacetic acid, or a mixture thereof,
- (c) about 20 mM of a buffer comprising citric acid and a pharmaceutically acceptable salt of citric acid;
- (d) about 6.9% (w/v) of a tonicity modifier;
- and
- (e) at least 90% (w/v) water;
- and
- having a pH of about 8.
An aqueous formulation, comprising:
- (a) about 0.5% (w/v) of a compound of Formula I, wherein Formula I is represented by:
- or a pharmaceutically acceptable salt thereof;
- (b) about 0.02% (w/v) of a chelating agent selected from ethylenediamine tetraacetic acid, a pharmaceutically acceptable salt of ethylenediamine tetraacetic acid, or a mixture thereof,
- (c) about 20 mM of a buffer comprising citric acid and a pharmaceutically acceptable salt of citric acid;
- (d) about 6.9% (w/v) sucrose;
- and
- (e) at least 90% (w/v) water;
- and
- having a pH of about 8.
28-57. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
78-84. (canceled)
Dependencies are inferred from the claim text.